Post hoc analyses demonstrated that differences between MFM32 scores at baseline and Month 24 in patients with Type 3 SMA did not reach statistical significance; this could be interpreted as a slower disease progression in individuals with Type 3 SMA, or this may be related to the smaller number of patients in this group.
← all excerpts
Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study.
1
—
—